Amphastar Pharmaceuticals (AMPH) Earns Media Sentiment Score of 0.18
News coverage about Amphastar Pharmaceuticals (NASDAQ:AMPH) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Amphastar Pharmaceuticals earned a coverage optimism score of 0.18 on Accern’s scale. Accern also assigned news stories about the company an impact score of 44.5908673324763 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Several analysts recently weighed in on AMPH shares. Raymond James Financial cut shares of Amphastar Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $18.00 price target on the stock. in a report on Thursday, November 9th. BMO Capital Markets lifted their price target on shares of Amphastar Pharmaceuticals from $16.00 to $17.00 and gave the company a “market perform” rating in a report on Friday, November 10th. Needham & Company LLC lifted their price target on shares of Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the company a “buy” rating in a report on Friday, December 1st. Zacks Investment Research cut shares of Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, December 27th. Finally, BidaskClub cut shares of Amphastar Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Tuesday, January 9th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $20.83.
Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) opened at $18.34 on Friday. Amphastar Pharmaceuticals has a fifty-two week low of $12.05 and a fifty-two week high of $19.95. The company has a market cap of $830.32, a price-to-earnings ratio of 120.40, a PEG ratio of 1.27 and a beta of 1.46. The company has a current ratio of 3.08, a quick ratio of 1.86 and a debt-to-equity ratio of 0.13.
ILLEGAL ACTIVITY WARNING: “Amphastar Pharmaceuticals (AMPH) Earns Media Sentiment Score of 0.18” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://www.watchlistnews.com/amphastar-pharmaceuticals-amph-earns-media-sentiment-score-of-0-18/1904128.html.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.